Gong Y[au] - Search Results

Year	Number of Results
1980	1
1981	1
1982	5
1983	2
1984	1
1985	4
1986	4
1987	2
1988	4
1989	5
1990	8
1991	11
1992	11
1993	14
1994	12
1995	18
1996	16
1997	9
1998	24
1999	32
2000	42
2001	46
2002	49
2003	84
2004	90
2005	123
2006	150
2007	183
2008	169
2009	216
2010	247
2011	294
2012	362
2013	410
2014	474
2015	530
2016	510
2017	641
2018	772
2019	924
2020	1028
2021	1174
2022	936

1

Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy.

Long H, Jia Q, Wang L, Fang W, Wang Z, Jiang T, Zhou F, Jin Z, Huang J, Zhou L, Hu C, Wang X, Zhang J, Ba Y, Gong Y, Zeng X, Zeng D, Su X, Alexander PB, Wang L, Wang L, Wan YY, Wang XF, Zhang L, Li QJ, Zhu B. Long H, et al. Among authors: gong y. Cancer Cell. 2022 Jun 13;40(6):674-693.e7. doi: 10.1016/j.ccell.2022.04.018. Epub 2022 May 19. Cancer Cell. 2022. PMID: 35594863

2

Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer.

Zhang JT, Liu SY, Gao W, Liu SM, Yan HH, Ji L, Chen Y, Gong Y, Lu HL, Lin JT, Yin K, Jiang BY, Nie Q, Liao RQ, Dong S, Guan Y, Dai P, Zhang XC, Yang JJ, Tu HY, Xia X, Yi X, Zhou Q, Zhong WZ, Yang XN, Wu YL. Zhang JT, et al. Among authors: gong y. Cancer Discov. 2022 Jul 6;12(7):1690-1701. doi: 10.1158/2159-8290.CD-21-1486. Cancer Discov. 2022. PMID: 35543554

3

Decoding the temporal and regional specification of microglia in the developing human brain.

Li Y, Li Z, Yang M, Wang F, Zhang Y, Li R, Li Q, Gong Y, Wang B, Fan B, Wang C, Chen L, Li H, Ong J, Teng Z, Jin L, Wang YL, Du P, Jiao J. Li Y, et al. Among authors: gong y. Cell Stem Cell. 2022 Apr 7;29(4):620-634.e6. doi: 10.1016/j.stem.2022.02.004. Epub 2022 Mar 3. Cell Stem Cell. 2022. PMID: 35245443

4

Ordered and deterministic cancer genome evolution after p53 loss.

Baslan T, Morris JP 4th, Zhao Z, Reyes J, Ho YJ, Tsanov KM, Bermeo J, Tian S, Zhang S, Askan G, Yavas A, Lecomte N, Erakky A, Varghese AM, Zhang A, Kendall J, Ghiban E, Chorbadjiev L, Wu J, Dimitrova N, Chadalavada K, Nanjangud GJ, Bandlamudi C, Gong Y, Donoghue MTA, Socci ND, Krasnitz A, Notta F, Leach SD, Iacobuzio-Donahue CA, Lowe SW. Baslan T, et al. Among authors: gong y. Nature. 2022 Aug;608(7924):795-802. doi: 10.1038/s41586-022-05082-5. Epub 2022 Aug 17. Nature. 2022. PMID: 35978189 Free PMC article.

5

PUMILIO proteins promote colorectal cancer growth via suppressing p21.

Gong Y, Liu Z, Yuan Y, Yang Z, Zhang J, Lu Q, Wang W, Fang C, Lin H, Liu S. Gong Y, et al. Nat Commun. 2022 Mar 25;13(1):1627. doi: 10.1038/s41467-022-29309-1. Nat Commun. 2022. PMID: 35338151 Free PMC article.

6

Irisin ameliorates neuroinflammation and neuronal apoptosis through integrin αVβ5/AMPK signaling pathway after intracerebral hemorrhage in mice.

Wang Y, Tian M, Tan J, Pei X, Lu C, Xin Y, Deng S, Zhao F, Gao Y, Gong Y. Wang Y, et al. Among authors: gong y. J Neuroinflammation. 2022 Apr 7;19(1):82. doi: 10.1186/s12974-022-02438-6. J Neuroinflammation. 2022. PMID: 35392928 Free PMC article.

7

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group. Wang J, et al. Among authors: gong y. Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576956 Clinical Trial.

8

In vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancer.

Ji P, Gong Y, Jin ML, Wu HL, Guo LW, Pei YC, Chai WJ, Jiang YZ, Liu Y, Ma XY, Di GH, Hu X, Shao ZM. Ji P, et al. Among authors: gong y. Sci Adv. 2022 Jul;8(26):eabl8247. doi: 10.1126/sciadv.abl8247. Epub 2022 Jun 29. Sci Adv. 2022. PMID: 35767614 Free PMC article.

9

FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.

Akinboro O, Larkins E, Pai-Scherf LH, Mathieu LN, Ren Y, Cheng J, Fiero MH, Fu W, Bi Y, Kalavar S, Jafri S, Mishra-Kalyani PS, Fourie Zirkelbach J, Li H, Zhao H, He K, Helms WS, Chuk MK, Wang M, Bulatao I, Herz J, Osborn BL, Xu Y, Liu J, Gong Y, Sickafuse S, Cohen R, Donoghue M, Pazdur R, Beaver JA, Singh H. Akinboro O, et al. Among authors: gong y. Clin Cancer Res. 2022 Jun 1;28(11):2221-2228. doi: 10.1158/1078-0432.CCR-21-3844. Clin Cancer Res. 2022. PMID: 35101885

10

KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming.

Na F, Pan X, Chen J, Chen X, Wang M, Chi P, You L, Zhang L, Zhong A, Zhao L, Dai S, Zhang M, Wang Y, Wang B, Zheng J, Wang Y, Xu J, Wang J, Wu B, Chen M, Liu H, Xue J, Huang M, Gong Y, Zhu J, Zhou L, Zhang Y, Yu M, Tian P, Fan M, Lu Z, Xue Z, Zhao Y, Yang H, Zhao C, Wang Y, Han J, Yang S, Xie D, Chen L, Zhong Q, Zeng M, Lowe SW, Lu Y, Liu Y, Wei Y, Chen C. Na F, et al. Among authors: gong y. Nat Cancer. 2022 Jun;3(6):753-767. doi: 10.1038/s43018-022-00361-6. Epub 2022 Apr 21. Nat Cancer. 2022. PMID: 35449309

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results